Mobile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in T...

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-020911-35

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus) and Peginterferon Alfa 2a (Pegasys) in Treatment Na�ve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the antiviral efficacy (sustained virologic response [SVR]; defined as undetectable HCV RNA 24 weeks following treatment cessation) of 16 and 24 weeks of response guided duration of therapy with GS-9190, GS-9256, ribavirin (RBV), and peginterferon alfa 2a (PEG).

Critère d'inclusion

  • Chronic hepatitis C virus infection

Liens